Aligos Therapeutics Inc. (ALGS), a clinical-stage biopharmaceutical company, on Wednesday presented positive data from ten presentations evaluating Pevifoscorvir sodium in treating chronic hepatitis B and other ongoing studies at the European Association for the Study of the Liver (EASL) congress, 2026.
Hepatitis B is one of the most common chronic viral infections, with over 2.34 million carriers worldwide. The virus is also the primary cause of liver cancer. The Hepatitis B virus (HBV) is diagnosed by detecting certain antigens, such as the hepatitis B e-antigen (HbeAg) or the hepatitis B surface antigen (HbsAg).
Pevifoscorvir sodium is an oral, small molecule, capsid assembly modulator-enhancer (CAM-E), that has shown antiviral activity by reducing the covalent closed circular DNA (cccDNA) reservoir, according to long-term follow up data from the Phase 1 study. The drug is being evaluated in combination with tenofovir disoproxil fumarate in the Phase 2 B-SUPREME study, in untreated HBeAg+ and HBeAg- adult patients of chronic HBV infection.
The new presented data from studies showed that untreated HbeAg+ patients who completed 96 weeks of pevifoscorvir sodium monotherapy, followed by nucleotide-analog therapy, showed decreased HBV and HBV RNA levels during the 24-week follow-up period. Additionally, HbsAg+ patients on the drug showed a reduction in HBV levels to below 3000 IU/ml, suggesting a functional cure regimen may be possible in combination with an antisense oligonucleotide (ASO) agent such as ALG-170675, developed with partner Amoytop.
Preclinical in vitro data for ALG-001075, the active parent moiety of pevifoscorvir sodium, demonstrated potent and durable suppression of HBeAg, HBsAg, and intracellular HBV RNAs with effects persisting after treatment withdrawal, indicating a reduction in cccDNA levels and transcriptional activity. The drug also showed additive synergistic antiviral effect with ALG-170675, a developing, potentially first-in-class ASO agent.
The company is also exploring ASO candidates for the treatment of the hepatitis delta virus (HDV), and a THR-Beta agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
ALGS closed Tuesday at $5.74, down 0.35%. In the pre-market, the stock is trading at $5.75, up 0.16%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.